Abstract

Pancreatic cysts are being detected at an increasing rate and are estimated to be present in 2 percent of the adult population. Unfortunately, current preoperative diagnostics do not sufficiently distinguish benign cystic lesions from those that harbor malignant potential. Missregulated pericellular proteolysis is a hallmark of invasive cancer, and therefore, we used a global substrate profiling strategy to discover differentiating protease activities in patient cyst fluid obtained through minimally invasive endoscopic sampling. We determined that the activities of the aspartyl proteases gastricsin and cathepsin E are highly increased in mucinous cysts. Profiling of gastricsin and cathepsin E activity using fluorescent peptide substrates differentiated mucinous from nonmucinous cysts with high sensitivity and specificity in a 110 patient cohort. Of particular note, gastricsin activity analysis demonstrated a specificity of 100% and sensitivity of 93%, significantly outperforming the most widely used biomarker, carcinoembryonic antigen. We propose that activity‐based detection of gastricsin and cathepsin E has the potential to replace current diagnostic tests for differentiating mucinous from nonmucinous cysts, leading to improved clinical management of these challenging and highly prevalent lesions.Support or Funding InformationThis study was supported by the following grants: NIH National Heart, Lung, And Blood Institute grant U54HL 119893 (to C. C.), NIH/NCATS UCSF‐CTSI grant UL1 TR000004 (to C. C.), and NIH grant A119685 (to K. K.).

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call